Press Releases

Press Releases

CAMBRIDGE, MA – February 23, 2011 – Quanterix Corporation, a single molecule diagnostics company providing technology with unprecedented sensitivity for the life science and in vitro diagnostics markets, today announced the online publication of a study that builds upon the company’s Single …
CAMBRIDGE, MA – February 22, 2011 – Quanterix Corporation, enabling a new generation of diagnostic tests based on revolutionary Single Molecule Array (SiMoA™) technology, today announced that it has entered into an evaluation agreement with Novartis Diagnostics on the potential use of Quanterix’s…
CAMBRIDGE, MA – December 17, 2010 – Quanterix, a single molecule diagnostics company providing technology with unprecedented sensitivity for the life science and in vitro diagnostics markets, today announced that David Okrongly, Ph.D., President and Chief Executive Officer, will present at the 3rd…
CAMBRIDGE, MA – December 1, 2010 – Quanterix Corporation announced today that Martin D. Madaus, Ph.D has joined the company’s Board as Executive Chairman. Dr. Madaus brings more than 20 years of experience in the diagnostics and life science industries, most recently serving as President, Chairman…
CAMBRIDGE, MA – November 2, 2010 – Quanterix Corporation, a single molecule technology company focused on developing a next generation diagnostics platform, announced today that it was awarded a total of $733,437 in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP…
DENVER – A new test could reliably detect early increases in prostate specific antigen (PSA) levels – a biomarker commonly used to measure the recurrence of prostate cancer – in men who have undergone prostate cancer-treating surgery. Earlier detection of these rising levels would allow men with…
CAMBRIDGE, MA – May 23, 2010 – Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company’s proprietary technology that demonstrates an unprecedented sensitivity…
CAMBRIDGE, MA – September 2, 2009 – Quanterix Corporation, the leader in single molecule detection, announced today that David Okrongly, Ph.D. has been appointed Chief Executive Officer and a member of the company’s Board of Directors. Dr. Okrongly replaces co-founder and interim CEO, Nicholas…
CAMBRIDGE, MA – November 11, 2008 – Quanterix Corporation, the leader in single molecule detection, announced today that Robert Corn, Ph.D. has joined its Scientific Advisory Board (SAB). Dr. Corn is a Professor in the Departments of Chemistry and Biomedical Engineering at the University of…
CAMBRIDGE, MA – September 30, 2008 – Quanterix Corporation, the leader in single molecule protein detection, announced today that it has been awarded a Phase I Small Business Innovative Research (SBIR) grant from the National Cancer Institute of the National Institutes of Health (NIH). This grant…